Linked Life Data

11225989

Source:http://linkedlifedata.com/resource/pubmed/id/11225989

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
11
pubmed:dateCreated
2001-2-27
pubmed:abstractText
The recently described CC chemokine, 6C-kine, is unique in that it contains -six rather than the usual four conserved cysteines typical of this family. Furthermore, murine 6C-kine binds to one of the CXC chemokine receptors CXCR3, in addition to its other known receptor CCR7. We have shown that two other ligands of CXCR3, IP-10 and MIG, are potent inhibitors of tumor growth in severe combined immunodeficiency (SCID) mice. We postulated that murine 6C-kine may also inhibit tumor growth via inhibition of angiogenesis in this model. SCID mice (n = 6 per group) inoculated with A549 human lung cancer cells were treated with either 6C-kine (100 ng intra-tumor injection every other day) or control protein for 8 weeks. Tumors from murine 6C-kine-treated mice (288 +/- 26 mm3) were significantly smaller than tumors from control treated mice (788 +/- 156 mm3, P = 0.005). Additionally, murine 6C-kine reduced metastases compared with controls (0.5 +/- 0.3 vs 3.0 +/- 1.2 metastases per animal, P = 0.05). Tumor vascularity (as assessed by vessel density counting) was reduced in murine 6C-kine-treated mice compared with controls. Murine 6C-kine had no direct effect on proliferation of A549 cells, and there were no differences in the infiltration of leukocyte sub-populations, assessed by flow cytometry, in the treatment groups. Interestingly, human 6C-kine, unlike murine 6C-kine, does not bind CXCR3 and had no anti-tumor effect in the same model. These data suggest that murine 6Ckine has anti-tumor effects independent of its leukocyte-recruiting activity. Furthermore, while not confirmatory, these data lend further support to the fact that CXCR3 may be the receptor for angiostatic CXC chemokines.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
0340-7004
pubmed:author
pubmed:issnType
Print
pubmed:volume
49
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
587-92
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:11225989-Angiogenesis Inhibitors, pubmed-meshheading:11225989-Animals, pubmed-meshheading:11225989-Carcinoma, Non-Small-Cell Lung, pubmed-meshheading:11225989-Cell Division, pubmed-meshheading:11225989-Chemokine CCL21, pubmed-meshheading:11225989-Chemokines, CC, pubmed-meshheading:11225989-Chimera, pubmed-meshheading:11225989-Female, pubmed-meshheading:11225989-Humans, pubmed-meshheading:11225989-Leukocytes, pubmed-meshheading:11225989-Lung Neoplasms, pubmed-meshheading:11225989-Mice, pubmed-meshheading:11225989-Mice, SCID, pubmed-meshheading:11225989-Neoplasm Metastasis, pubmed-meshheading:11225989-Neoplasms, Experimental, pubmed-meshheading:11225989-Neovascularization, Pathologic, pubmed-meshheading:11225989-Receptors, CXCR3, pubmed-meshheading:11225989-Receptors, Chemokine, pubmed-meshheading:11225989-Tumor Cells, Cultured
pubmed:year
2001
pubmed:articleTitle
The murine CC chemokine, 6C-kine, inhibits tumor growth and angiogenesis in a human lung cancer SCID mouse model.
pubmed:affiliation
Department of Internal Medicine, University of Michigan Medical School, Ann Arbor 48109-0642, USA. darenber@umich.edu
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Research Support, Non-U.S. Gov't